Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
viernes, octubre 02
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Capricor Therapeutics Inc
CAPR
NASDAQ
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$8.94
-0.53
-5.6%
Últ. Act.: Oct 2, 7:58 AM
$8.98
-0.49
-5.17%
Get Report
Panorámica general
Noticias
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Propiedad
Comparar
Opciones
Informe de acciones
Privacy Manager
Capricor Therapeutics Financials
Capricor Therapeutics (CAPR) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
Capricor Therapeutics Remains Optimistic about Deramiocel FDA Approval
Capricor Therapeutics highlights Deramiocel's FDA review, commercial readiness, and cash position of $approximately $237.9 million.
Vandana Singh
Capricor Therapeutics (CAPR) Shares Soar Over 67% After Hours: Here's Why
Capricor Therapeutics shares surged 67.22% after hours following quarterly results and an update on the FDA review of its application.
Mohd Haider
PRO
Capricor Therapeutics Q2 EPS $(0.70) Misses $(0.58) Estimate
Capricor Therapeutics (NASDAQ:CAPR) reported quarterly losses of $(0.70) per share which missed the analyst consensus estimate of $(0.58) by 20.69 percent. This is a 22.81 percent decrease over losses of $(0.57) per
Benzinga Newsdesk
PRO
Capricor Therapeutics Q1 EPS $(0.59) Misses $(0.50) Estimate
Benzinga Newsdesk
Earnings Scheduled For May 12, 2026
Benzinga Insights
PRO
Capricor Therapeutics Believes That, Based On The Current Operating Plan And Financial Resources, Its Available Cash, Cash Equivalents And Marketable Securities Will Be Sufficient To Cover Anticipated Expenses And Capital Requirements Through 2027
Expectation Excludes Any Additional Potential Milestone Payments Under The Commercialization And Distribution Agreements With Nippon Shinyaku, As Well As Any Strategic Use Of Capital Not Currently In The Company's Base
Benzinga Newsdesk
